[Evaluation of conservative treatment for Graves-Basedow disease depending on the clinical severity of thyrotoxicosis, blood group (ABO) and HLA A1, B8 antigens].
The purpose of the study was to determine whether such factors as: initial exacerbation of thyrotoxicosis, blood group (ABO) and the presence of HLA A1, B8 antigens have an influence on the effectiveness of the conservative treatment of thyrotoxicosis in Graves-Basedow disease (G-B disease). Studies were carried out in two groups of 32 women each with G-B disease. The patients in group I were 28-61 years of age, in whom euthyroid state lasting at least 5 years was attained after treatment with methimazole on average over a 15.4 month cycle. The age of the patients in group II was 27-61 years, in whom at least one relapse occurred in 5-year follow-up. The groups of patients did not differ significantly in the clinical exacerbation of thyrotoxicosis measured in the scale of Zgliczyński. The frequencies of occurrence of the particular clinical symptoms of thyrotoxicosis did not differ in both groups, except diarrhoea with occurred significantly more frequently in women of group II (47%) in comparison with group I (15.6%). No characteristic differences were found between both groups in the occurrence of blood group O, A, B, AB and antigen HLA A1. Statistically significant difference was found in the occurrence of antigen HLA B8 and phenotype HLA A1 B8, both between the patient groups and control. Their influence expressed by odds ratio OR = 3 indicated that the chances of effective conservative treatment for the patients in group II were three times smaller than for those in group I.
Maciejko-Meresta
B
B
Kliniki Ogólnej Chorób Wewnetrznych Akademii Medycznej w Lublinie.
D000017:ABO Blood-Group System; D000328:Adult; D005260:Female; D006111:Graves Disease / Q000150:complications / Q000503:physiopathology / Q000628:therapy*; D006680:HLA Antigens / Q000276:immunology*; D006801:Humans; D008713:Methimazole / Q000627:therapeutic use; D008875:Middle Aged; D013971:Thyrotoxicosis / Q000209:etiology
D000017:ABO Blood-Group System; D006680:HLA Antigens; D008713:Methimazole
Ocena skuteczności leczenia zachowawczego choroby Graves-Basedowa w zalezności od klinicznego nasilenia tyreotoksykozy, grupy krwi układu ABO, antygenów HLA A1, B8.